A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
11/2011
11/23/2011	CN102257008A Antibodies against human angiopoietin 2
11/23/2011	CN102256997A Torque teno virus (ttv) isolates and compositions
11/23/2011	CN102256623A Neuroinvasion inhibitor
11/23/2011	CN102256621A Pain treatment
11/23/2011	CN102256620A Immunotherapeutic compositions for the treatment of alzheimer's disease
11/23/2011	CN102256619A Ex-vivo passive protection bacteremia assay
11/23/2011	CN102256594A Modulation of toll-like receptor 8 expression by antisense oligonucleotides
11/23/2011	CN102251013A Antibody and antigen for recognizing tumor initiator cell and application thereof
11/23/2011	CN102250852A Clone and expression of bovine recombinant alpha-1,3-galactoside transferase (GT)
11/23/2011	CN102250843A Genetic engineering marked attenuated vaccine strain of porcine reproductive and respiratory syndrome virus and application thereof
11/23/2011	CN102250252A Gastrin-releasing peptide (GRP) guided fusion protein
11/23/2011	CN102250250A Human-mouse chimeric anti-human CD19 antibody Hm2E8b and use thereof
11/23/2011	CN102250249A Anti-VEGF/PDGFR (Vascular Endothelial Growth Factor/Platelet-Derived Growth Factor Receptor) beta double-specificity antibody and application thereof
11/23/2011	CN102250248A Anti-VEGF/ANG2 bispecific antibody, and application thereof
11/23/2011	CN102250247A Bispecific antibody to VEGF/ANG2 and application thereof
11/23/2011	CN102250246A Bispecific antibody to VEGF/PDGFR beta and application thereof
11/23/2011	CN102250245A Bispecific antibody capable of resisting B cell lymphoma and application thereof
11/23/2011	CN102250244A Human prolactin receptor antibody and application thereof
11/23/2011	CN102250243A Antibody to interleukins-15
11/23/2011	CN102250239A Protein capable of combining with vp60 protein of rabbit hemorrhagic disease virus and use thereof
11/23/2011	CN102250231A Chonorchis sinensis specific PPMP antigens and application thereof
11/23/2011	CN102247606A DNA (deoxyribonucleic acid) level-based highly pathogenic blue-eared pig disease JEV (Japanese encephalitis virus) replicon vaccine and application thereof
11/23/2011	CN102247605A Antiviral effect of novel pathogen recognition molecule
11/23/2011	CN102247604A Angiotensin II receptor 1 type polypeptide-vector vaccine and application thereof
11/23/2011	CN102247600A Method for preparing diluent for pseudorabies live vaccine
11/23/2011	CN102247595A Application of polyinosinic-polycytidylic acid (poly I:C) combined dimo-thylidioctyl ammonium bromide (DDA) mixed adjuvant to preparation of tuberculosis subunit vaccines
11/23/2011	CN102247594A Water-in-oil single-phase emulsification adjuvant and preparation method thereof
11/23/2011	CN102247593A Preparation and application of recombinant newcastle disease virus-modified autologous tumor vaccine
11/23/2011	CN102247327A Hazard-free microencapsulation for structurally delicate agents, an application of stable aqueous-aqueous emulsion
11/23/2011	CN102091327B Preparation method of dendritic cell (DC) vaccine loaded with autologous tumor associated holoantigen
11/23/2011	CN101724011B Preparation method and application of tumor tissue complete antigen
11/23/2011	CN101624580B Recombinant baculovirus expressing manually modified and synthesized influenza A H1N1 virus HA-NA-M1 gene
11/23/2011	CN101550192B Monoclonal antibody K42-D2 of antihuman granzyme K and hybridoma cell line for excreting same
11/23/2011	CN101492505B Specific combined polypeptide for lung cancer, preparation and uses thereof
11/23/2011	CN101330930B Therapeutic agent for heart disease
11/23/2011	CN101134778B Monoclonal antibody of esophagus cancer resistant blood vessel endothelium cell
11/22/2011	US8063188 Anti-myostatin antibodies
11/22/2011	US8063187 Methods and compositions for inhibiting CD32B expressing cells
11/22/2011	US8063186 Antibodies to PRO7436 polypeptides
11/22/2011	US8063183 Ephrin extracellular domain polypeptides for use in diagnosis prevention and treatment of cell proliferative disorders
11/22/2011	US8063016 Retro-inverso peptides derived from interleukin-6
11/22/2011	US8062906 B-lymphocyte stimulator binding polypeptides and methods based thereon
11/22/2011	US8062864 Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
11/22/2011	US8062646 Tissue vaccines and uses thereof
11/22/2011	US8062645 kits for vaccination of poultry, comprising bottles and package inserts with administration instructions; the bottles comprise an attenuated and an inactivated immunogens, excipients, diluents or vehicles
11/22/2011	US8062644 Immunogens from uropathogenic Escherichia coli
11/22/2011	US8062643 Use of neurotoxin therapy for treatment of urologic and related disorders
11/22/2011	US8062642 Production of papillomavirus capsid protein and virus-like particles
11/22/2011	US8062641 Immunogens for meningitidis-A vaccines
11/22/2011	US8062640 High affinity human antibodies to PCSK9
11/22/2011	US8062639 Antibodies to bufalin prevent inhibition of Na/K ATPase and prolong survival in shock
11/22/2011	US8062638 Prevention and treatment of diseases associated with blood coagulation
11/22/2011	US8062637 Methods of ameliorating inflammatory disease using an uPA antagonist
11/22/2011	US8062636 Antibody therapy
11/22/2011	US8062635 Bispecific antibody substituting for functional proteins
11/22/2011	US8062634 Methods of treating cutaneous ulcers and grafts using agonist antibodies to IL-23 receptor
11/22/2011	CA2513655C Use of tryptanthrin compounds for immune potentiation
11/22/2011	CA2482973C Microparticles comprising carbohydrate beads covalently linked with allergen
11/22/2011	CA2456025C An implantable and sealable system for unidirectional delivery of therapeutic agents to tissues
11/22/2011	CA2430013C Transgenic transchromosomal rodents for making human antibodies
11/22/2011	CA2372511C Secreted and transmembrane polypeptides and nucleic acids encoding the same
11/22/2011	CA2344740C Mutant cholera holotoxin as an adjuvant
11/22/2011	CA2258518C Recognition molecules interacting specifically with the active site or cleft of a target molecule
11/22/2011	CA2257826C Helicobacter pylori adhesin binding group antigen
11/17/2011	WO2011143665A1 Treatment methods
11/17/2011	WO2011143656A2 Compositions and methods of identifying tumor specific neoantigens
11/17/2011	WO2011143653A2 Recombinant hcmv and rhcmv vectors and uses thereof
11/17/2011	WO2011143650A2 Recombinant hcmv and rhcmv vectors and uses thereof
11/17/2011	WO2011143624A2 Humanized and chimeric monoclonal antibodies to cd47
11/17/2011	WO2011143623A1 Ospa chimeras and use thereof in vaccines
11/17/2011	WO2011143617A1 Chimeric ospa genes, proteins, and methods of use thereof
11/17/2011	WO2011143614A1 Enhanced death receptor agonists
11/17/2011	WO2011143562A2 Il-1 binding proteins
11/17/2011	WO2011143538A1 Extracorporeal devices and methods of treating complications of pregnancy
11/17/2011	WO2011143482A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
11/17/2011	WO2011143461A2 Heat shock proteins as autoantigens
11/17/2011	WO2011143414A1 RECOMBINANTLY PRODUCED ANTIBODIES TARGETING ErbB SIGNALING MOLECULES AND METHODS OF USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF DISEASE
11/17/2011	WO2011143408A1 Use of neuropilin-1 antagonists for the treatment of cancer
11/17/2011	WO2011143318A2 Anti-fgfr2 antibodies
11/17/2011	WO2011143307A1 High concentration antibody formulations
11/17/2011	WO2011142573A2 Vaccine composition containing a wta as an active ingredient
11/17/2011	WO2011141926A2 Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
11/17/2011	WO2011141819A1 Improved methods for preparing squalene
11/17/2011	WO2011141451A1 Dna based multivalent vaccine against mycobacterium tuberculosis, encoding ag85a, tb9.8, tb10.4 and acr2 antigens.
11/17/2011	WO2011141443A1 Vaccine against mycoplasma hyopneumoniae, suitable for administration in the presence of maternally derived antibodies
11/17/2011	WO2011140828A1 Gep antibody and uses thereof
11/17/2011	WO2011140827A1 Antibody and diagnostic kit
11/17/2011	WO2011140634A2 The n-domain of carcinoembryonic antigen and compositions, methods and uses thereof
11/17/2011	WO2011119888A3 N-cadherin: target for cancer diagnosis and therapy
11/17/2011	WO2011117648A3 Disulfide stabilised antibodies and fragments thereof
11/17/2011	WO2011117506A3 Adjuvant diluents for live vaccines for pig diseases
11/17/2011	WO2011112805A3 Compositions and methods for screening for lyme disease
11/17/2011	WO2011106705A3 Dna-protein vaccination protocols
11/17/2011	WO2011093594A3 Vaccine vehicle including mycobacterial cell-wall skeleton and method for preparing vaccine using the same
11/17/2011	WO2011091319A3 Dendritic cell vaccines
11/17/2011	WO2011089183A3 Anticoagulant antidotes
11/17/2011	WO2011088272A9 Selective ampd2 inhibitors and methods for using the same
11/17/2011	WO2011082369A3 Injectable formulations for parenteral administration
11/17/2011	WO2011079260A3 Stabilized virus like particles having enhanced mucosal immunogenicity
11/17/2011	WO2011078590A3 Ultraviolet protection composition comprising a blt2 inhibitor

1 ... 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 ... 1823